Last updated: February 25, 2026
What is the drug associated with NDC 42799-0961?
NDC 42799-0961 corresponds to Sermorelin Acetate, a synthetic peptide mimicking endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce more growth hormone, used primarily for growth hormone deficiency in children and adults.
What is the current market landscape?
Approved indications and usage
- Approved for growth hormone deficiency treatment.
- Used off-label for anti-aging and muscle mass augmentation, though not FDA-approved for these purposes.
Market size and demand
- The global growth hormone therapy market was valued at approximately USD 4.6 billion in 2022.
- CAGR projected at 4.8% through 2030, driven by aging populations and chronic growth hormone deficiencies.
- The peptide therapeutics market, to which sermorelin belongs, is growing at around 8.2% annually, reaching USD 27 billion by 2025.
Competitive landscape
- Main competitors include brands like Norditropin, Genotropin (both recombinant GH), and other peptide-based therapies.
- Biosimilars and generics are emerging, pressuring prices.
- No currently approved biosimilar for sermorelin, but compounded formulations are prevalent.
Regulatory environment
- FDA approval exists for sermorelin (e.g., Geref®), with limited regulatory scrutiny compared to recombinant growth hormones.
- No recent label changes or restrictions reported for sermorelin or its formulations.
Price trends and projections
Current average prices
| Manufacturer/Source |
Price per 1 mL vial |
Notes |
| Branded sermorelin (Geref) |
USD 250–400 |
Varies depending on supplier and location |
| Compounded formulations |
USD 50–150 |
Prices are lower; quality and compliance vary |
| Biosimilar/Generics |
Not commercially available |
Expected within the next 3–5 years |
Price drivers
- Small molecule growth hormone injections cost USD 300–USD 1,000 per dose, averaging USD 650.
- Peptide therapies like sermorelin are significantly cheaper, but compounded products undermine pricing distinctions.
- Regulatory approval for biosimilars could decrease prices by 20–50%.
Future price projections (2023–2028)
- Branded sermorelin prices are expected to decline at an annual rate of 5–8% due to increased competition and biosimilar entry.
- Compound formulations may see minimal variation, but quality control concerns could affect market penetration.
- Biosimilar sermorelin could enter the market by 2025, reducing average prices by up to 40%.
Market entry barriers and opportunities
- Barriers: Regulatory approval process for biosimilars, manufacturing scale-up, patent protections on original formulations.
- Opportunities: Growth in peptide therapeutics, potential approvals for biosimilars, expanding indications beyond growth hormone deficiency.
Summary table: Price projections (USD per vial, 2023–2028)
| Year |
Branded sermorelin |
Biosimilar (expected 2025) |
Compounded formulations |
| 2023 |
250–400 |
200–350 |
50–150 |
| 2024 |
237–380 |
180–330 |
50–150 |
| 2025 |
225–360 |
150–300 |
50–150 |
| 2026 |
213–342 |
130–270 |
50–150 |
| 2027 |
202–324 |
110–250 |
50–150 |
| 2028 |
192–308 |
90–230 |
50–150 |
Key factors influencing future market dynamics
- Regulatory pathways for biosimilars and generics.
- Physician acceptance and insurance reimbursement policies.
- Technological advancements in peptide synthesis.
Key Takeaways
- The sermorelin market is growing with increasing demand for peptide therapies.
- Prices are declining due to biosimilar entry expected by 2025.
- Branded formulations are likely to see value erosion at approximately 5-8% annually.
- Compound formulations dominate the lower-price segment but face quality and regulatory challenges.
- Significant growth opportunities exist in expanding indications and regulatory approvals.
FAQs
Q1: What is the main competitor to sermorelin in growth hormone therapy?
Recombinant growth hormones like Norditropin and Genotropin dominate the market.
Q2: When are biosimilars for sermorelin expected to enter the market?
Likely around 2025, contingent on regulatory approval and patent landscapes.
Q3: How does the price of compounded sermorelin compare to branded versions?
Compounded forms typically cost USD 50–150 per vial, significantly cheaper but with variable quality.
Q4: What factors could accelerate biosimilar adoption?
Regulatory approvals, insurer acceptance, and technological innovations reducing manufacturing costs.
Q5: What future trends could impact sermorelin prices?
Regulatory changes, market entry of biosimilars, and expanded approved indications.
Sources
- MarketsandMarkets. (2022). Peptide Therapeutics Market by Application, End-User, and Region.
- IQVIA. (2022). Global Growth Hormone Market Reports.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Label Changes.
- Grand View Research. (2023). Peptide Market Size, Share & Trends Analysis.
- Statista. (2022). Growth hormone therapy market data.
